Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2021-11-05 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
110年第3季資產負債表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated balance sheet with detailed financial data for multiple periods, including specific asset, liability, and equity line items. The data is presented for the third quarter of the year 110 (Taiwan calendar, corresponding to 2021) and includes comparative figures for previous periods. The presence of actual financial statements with substantive financial data for a period shorter than a full fiscal year indicates this is a quarterly or interim financial report. The document length is 3839 characters, which is relatively short but contains detailed financial tables, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-11-05 Chinese
公告本公司提報董事會財務報告之相關數據。
Regulatory Filings Classification · 95% confidence The document is a financial announcement from a company (旭富) providing summarized financial data for the period from January 1 to September 30, 2021. It includes key financial figures such as revenue, gross profit, operating profit, net profit, earnings per share, total assets, liabilities, and equity. The document states it is reporting data submitted to the board of directors on 110/11/05 (Taiwan calendar year 110 corresponds to 2021). The length is short (891 characters) and it is a summary of financial results rather than a full report. It does not contain detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory announcement of financial data. Given the nature and length, this fits best as a Regulatory Filing (RNS) rather than a full Interim Report or Annual Report.
2021-11-05 Chinese
公告本公司以自地委建方式簽訂工程合約
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the signing of a construction contract for a factory building project. It includes details such as contract type, parties involved, contract amount, project location, and board approval dates. The document is short (1230 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about a specific contract transaction rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-19 Chinese
公告本公司高流動性資產、短期借款、應付短期票券及 一年內到期之長期負債。
Regulatory Filings Classification · 95% confidence The document is a short announcement (784 characters) from a listed company providing specific financial data related to high liquidity assets, short-term borrowings, short-term notes payable, and long-term liabilities due within one year as of September 2021. It references a regulatory clause and a specific date but does not contain comprehensive financial statements or detailed analysis. The document is essentially a regulatory disclosure of financial position items rather than a full financial report or earnings release. It is not a report publication announcement since it contains actual data, but it is a regulatory filing type of announcement. Therefore, the best classification is Regulatory Filings (RNS).
2021-10-19 Chinese
110年09月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, managers, and major shareholders. It includes data on shares held at appointment, changes during the month, and current holdings, with specific mention of identities such as chairman, vice chairman, directors, managers, and their related parties. The content is focused on insider shareholding disclosures rather than financial results, management changes, or meeting materials. This type of document aligns with the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is substantial and contains actual data, not just an announcement or certification. Therefore, the appropriate classification is DIRS.
2021-10-08 Chinese
110年09月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 旭富製藥科技股份有限公司. It lists share counts held by directors, officers, and major shareholders, including pledged shares and related party holdings. There is no indication of financial statements, earnings data, or management discussion. The document is focused on insider shareholdings and their changes, which aligns with reporting on personal share transactions or holdings by company directors and executives. The document length is 3148 characters, which is relatively short and focused on insider shareholding data. Therefore, the most appropriate classification is Director's Dealing (DIRS).
2021-10-08 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.